Literature DB >> 12177102

Factorial design considerations.

Stephanie Green1, Ping-Yu Liu, Janet O'Sullivan.   

Abstract

PURPOSE: Factorial designs may be proposed to test extra questions within a clinical trial. A common approach to sample size and analysis for factorial trials assumes no statistical interactions and does not adjust for multiple testing. This investigation considered the trade-off between potential gains from testing more questions with fewer patients versus how often a factorial trial might arrive at an incorrect conclusion.
METHODS: A simulation study of a 2 x 2 design (observation v chemotherapy v radiation therapy v the combination) was performed under various conditions, including effect of one, both, or neither treatment and absence or presence of statistical interaction (effect of one treatment differed according to the presence of the other). Three analysis approaches were investigated, one assuming no interaction, a second testing first for interaction, and the third testing for interaction as well as adjusting for multiple testing. The approaches were compared with respect to the probability of selecting the correct treatment arm.
RESULTS: No one approach was superior. Testing for interaction was beneficial in some settings but detrimental in others. Under some scenarios, the factorial design improved efficiency, but under others, all three approaches resulted in poor probability of selecting the correct treatment arm at the end of the trial.
CONCLUSION: Extra efficiency is possible, but it is difficult to predict when favorable conditions exist. If a factorial design is used, potential efficiency gains should be weighed against potential loss of power to arrive at the correct conclusion under possible scenarios of interest.

Entities:  

Mesh:

Year:  2002        PMID: 12177102     DOI: 10.1200/JCO.2002.03.003

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  24 in total

Review 1.  Designing clinical trials for brain tumors: the next generation.

Authors:  Mark R Gilbert
Journal:  Curr Oncol Rep       Date:  2007-01       Impact factor: 5.075

2.  Factorial clinical trials: a new approach to phase II neuro-oncology studies.

Authors:  Fabio M Iwamoto; Andrew B Lassman
Journal:  Neuro Oncol       Date:  2014-12-01       Impact factor: 12.300

Review 3.  Two-by-Two Factorial Cancer Treatment Trials: Is Sufficient Attention Being Paid to Possible Interactions?

Authors:  Boris Freidlin; Edward L Korn
Journal:  J Natl Cancer Inst       Date:  2017-09-01       Impact factor: 13.506

4.  Sample Size Requirements and Study Duration for Testing Main Effects and Interactions in Completely Randomized Factorial Designs When Time to Event is the Outcome.

Authors:  Barry Kurt Moser; Susan Halabi
Journal:  Commun Stat Theory Methods       Date:  2015       Impact factor: 0.893

5.  Implementing Clinical Research Using Factorial Designs: A Primer.

Authors:  Timothy B Baker; Stevens S Smith; Daniel M Bolt; Wei-Yin Loh; Robin Mermelstein; Michael C Fiore; Megan E Piper; Linda M Collins
Journal:  Behav Ther       Date:  2017-01-07

6.  Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).

Authors:  Eric A Klein; Ian M Thompson; Catherine M Tangen; John J Crowley; M Scott Lucia; Phyllis J Goodman; Lori M Minasian; Leslie G Ford; Howard L Parnes; J Michael Gaziano; Daniel D Karp; Michael M Lieber; Philip J Walther; Laurence Klotz; J Kellogg Parsons; Joseph L Chin; Amy K Darke; Scott M Lippman; Gary E Goodman; Frank L Meyskens; Laurence H Baker
Journal:  JAMA       Date:  2011-10-12       Impact factor: 56.272

7.  Rationale and design: telephone-delivered behavioral skills interventions for Blacks with Type 2 diabetes.

Authors:  Leonard E Egede; Joni L Strom; Valerie L Durkalski; Patrick D Mauldin; William P Moran
Journal:  Trials       Date:  2010-03-29       Impact factor: 2.279

8.  Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival.

Authors:  William E Carson; Joseph M Unger; Jeffrey A Sosman; Lawrence E Flaherty; Ralph J Tuthill; Mark J Porter; John A Thompson; Raymond A Kempf; Megan Othus; Antoni Ribas; Vernon K Sondak
Journal:  Cancer Immunol Res       Date:  2014-07-03       Impact factor: 11.151

9.  Developing multicomponent interventions using fractional factorial designs.

Authors:  Bibhas Chakraborty; Linda M Collins; Victor J Strecher; Susan A Murphy
Journal:  Stat Med       Date:  2009-09-20       Impact factor: 2.373

10.  Comparison of a phased experimental approach and a single randomized clinical trial for developing multicomponent behavioral interventions.

Authors:  Linda M Collins; Bibhas Chakraborty; Susan A Murphy; Victor Strecher
Journal:  Clin Trials       Date:  2009-02       Impact factor: 2.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.